Denzil Moraes, MD
Interventional Cardiology · Baton Rouge, LANPI 1952381980
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $759,046 of the $901,405 with a category attached, or 84.2%. 42 manufacturers reported payments, led by Johnson & Johnson at 30.6% of the total. Reporting peaked in 2019 at $228,322 and has fallen 84.9% since, to $34,564 in 2025. Among interventional cardiology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,320 payments — averaging $682.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$275K
- Boehringer Ingelheim$263K
- Esperion Therapeutics, Inc.$200K
- Lilly USA, LLC$117K
- Novartis$36K
- Actelion Pharmaceuticals US, Inc.$1K
- plus $8K from 36 others
Across 37 payments — averaging $12,248 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$424K
- AstraZeneca$18K
- Amgen$12K
What the payments were for
- Consulting fees$6,0501%
- Speaking & faculty fees$759,04684%
- Travel & lodging$104,82112%
- Food & beverage$31,0693%
- Education$4030%
- Other$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$373,497
- XARELTO$271,156
- NEXLIZET$198,561
- NEXLETOL$198,561
- ENTRESTO$34,177
- RESOLUTE ONYX$379
- Assure WCD$261
- Resolute$257
- AccuCinch$155
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$150
- Impella$145
- Barostim Neo System$141
- LEXISCAN$125
- Kerendia$122
- Repatha$122
- LifeVest$120
- FARXIGA$112
- ZEPBOUND$105
How this compares
$901,405 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 585 | $562,062 |
| EliquisApixaban | 342 | $354,956 |
| JardianceEmpagliflozin | 361 | $346,020 |
| OpsumitMacitentan | 21 | $287,456 |
| EntrestoSacubitril/Valsartan | 226 | $279,590 |
| Repatha SureclickEvolocumab | 114 | $112,937 |
| NexlizetBempedoic Acid/Ezetimibe | 91 | $62,045 |
| NexletolBempedoic Acid | 70 | $54,010 |
| BrilintaTicagrelor | 27 | $26,628 |
| VascepaIcosapent Ethyl | 50 | $25,274 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $24,958 |
| Metoprolol Succinate | 1,181 | $14,770 |
| Atorvastatin Calcium | 1,104 | $12,944 |
| Icosapent Ethyl | 21 | $11,280 |
| FarxigaDapagliflozin Propanediol | 15 | $11,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $275,404 | $562,062585 claims |
| PfizerEliquis | $382 | $354,956342 claims |
| Boehringer IngelheimJardiance | $263,335 | $346,020361 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,386 | $287,45621 claims |
| NovartisEntresto | $35,514 | $279,590226 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $200,322 | $116,056161 claims |
| AstraZenecaBrilinta, Farxiga | $351 | $37,77442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Jorge CastellanosBaton Rouge$185K
- Venkata GadiBaton Rouge$117K
- Steven KelleyBaton Rouge$116K
- Garland GreenBaton Rouge$37K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Daniel FontenotBaton Rouge$16K
- Amit PatelBaton Rouge$16K
- Craig WalkerHouma$5M
- Ankur LodhaLafayette$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.